TC
IMGN

TFS Capital’s Immunogen Inc IMGN Stock Holding History

TFS Capital’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,159
Closed -$72K – 399
2017
Q2 		$72K Buy
+10,159
New +$46.5K 0.03% 576
2017
Q1 		– Sell
-28,988
Closed -$59K – 890
2016
Q4 		$59K Buy
28,988
+15,450
+114% +$31K 0.02% 682
2016
Q3 		$36K Sell
13,538
-3,491
-21% -$10.2K 0.01% 715
2016
Q2 		$52K Buy
+17,029
New +$107K 0.01% 913
2016
Q1 		– Sell
-97,566
Closed -$1.32M – 1123
2015
Q4 		$1.32M Buy
+97,566
New +$1.2M 0.14% 252
2015
Q3 		– Sell
-62,296
Closed -$896K – 1074
2015
Q2 		$896K Sell
62,296
-41,970
-40% -$461K 0.09% 368
2015
Q1 		$933K Buy
104,266
+49,177
+89% +$356K 0.09% 370
2014
Q4 		$336K Sell
55,089
-15,275
-22% -$140K 0.03% 698
2014
Q3 		$745K Buy
70,364
+25,287
+56% +$286K 0.06% 464
2014
Q2 		$534K Buy
+45,077
New +$566K 0.04% 620

Other funds holding IMGN

ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

TFS Capital's IMGN Position: Q3 2017 in Review

TFS Capital sold out of Immunogen Inc (IMGN) in Q3 2017, closing a stake of 10,159 shares — an estimated $72K sold.

TFS Capital first reported a position in IMGN in Q2 2014 and held it in 10 quarters. The position peaked at $1.32M in Q4 2015. 180 funds tracked by Wall St. Rank hold IMGN as of Q3 2017.

  • TFS Capital reported no remaining Immunogen Inc position as of Q3 2017 after selling out during the quarter.
  • TFS Capital sold 10,159 Immunogen Inc shares in Q3 2017, an estimated $72K.
  • TFS Capital first reported a position in Immunogen Inc in Q2 2014 and held it in 10 quarters.
  • TFS Capital's Immunogen Inc position peaked at $1.32M in Q4 2015.
  • 180 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.